The relationship between Alzheimer's-related brain atrophy patterns and sleep macro-architecture.

Sleep is increasingly recognized as a major risk factor for neurodegenerative disorders such as Alzheimer's disease (AD). Using an magnetic resonance imaging (MRI)-based AD score based on clinical data from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI1) case-control cohort, we investigated the associations between polysomnography-based sleep macro-architecture and AD-related brain atrophy patterns in 712 pre-symptomatic, healthy subjects from the population-based Study of Health in Pomerania. We identified a robust inverse association between slow-wave sleep and the AD marker (estimate: -0.019; 95% confidence interval: -0.03 to -0.0076; false discovery rate [FDR] = 0.0041), as well as with gray matter (GM) thicknesses in typical individual cortical AD-signature regions. No effects were identified regarding rapid eye movement or non-rapid eye movement (NREM) stage 2 sleep, and NREM stage 1 was positively associated with GM thickness, mainly in the prefrontal cortical regions. There is a cross-sectional relationship between AD-related neurodegenerative patterns and the proportion of sleep spent in slow-wave sleep.

Informations de copyright

© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Déclaration de conflit d'intérêts

H.J.G. has received travel grants and speaker honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag, as well as research funding from Fresenius Medical Care. H.J.G. had personal contracts approved by the university administration for speaker honoraria and one IIT with Fresenius Medical Care. T.P. received travel grants from Jazz Pharma, Löwenstein Medical, and the German Sleep Society, as well as speaker honoraria from Jazz Pharma, Löwenstein Medical, and Neuwirth, and research funding from the European Union, the German Israel Foundation and the Saratov state University. T.P. is on the advisory board of Philips, Crebra, and Nukute (unpaid); an Adcom member of the IEEE Biomedical Engineering Society (unpaid); and the president of the German Sleep Society (unpaid), and received consulting fees from Cerebra, Philips (paid to the institution), NovaResp Technologies (paid to the institution), Sleepimage (paid to the institution), and the National Sleep Foundation; sleep measuring devices from Neurovirtual and Sleepon; and holds shares in Advanced Sleep Research, The Siestagroup GmbH and Nukute. R.E. has received speaker honoraria from Berlin Chemie, AstraZeneca, and Janssen as well as consulting fees from LungPacer and OMT, and is a member of the LungPacer and Janssen advisory board. I.F. received grants from ResMed and Löwenstein Medical as well as consulting fees from ResMed, Stada, Bioproject, and Idorsia, and lecture honoraria from Medice, Henning, Idorsia, Bioprojet, Jazz Pharma, and ResMed. The remaining authors have nothing to declare. Author disclosures are available in the supporting information.